Understanding futility in pancreaticoduodenectomy: Insights from a national cohort
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27773 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Clayton T Marcinak und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Pancreaticoduodenectomy, Pancreatic Neoplasms, Medical Futility, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: BLRD VA, NCI NIH HHS, NHGRI NIH HHS.
Abstract (Originalsprache)
Background and Objectives Pancreaticoduodenectomy (PD), the only surgical option for right‐sided pancreatic ductal adenocarcinoma (PDAC), carries significant morbidity. Not all patients may be deriving a survival benefit from this operation. We sought to identify the rate of futile PD and its associated factors in a large national cohort.
Methods
We performed a retrospective analysis using the National Cancer Database (2004–2020), including all patients who underwent PD for non‐metastatic PDAC. The primary outcome was operative futility, which was defined as death within 12 months of diagnosis despite PD. Multivariable regression was used to identify factors associated with futility. We performed a subgroup analysis on patients who received neoadjuvant systemic therapy.
Results
Data from 66 326 patients were analyzed, and 16 772 (25.3%) underwent PD that met criteria for futility. Macroscopically positive margins (odds ratio [OR]: 2.87; 95% confidence interval [CI]: 2.36–3.48), poor tumor differentiation (OR: 2.44; 95% CI: 2.25–2.65), and N2 nodal stage (OR: 2.09; 95% CI: 1.98–2.20) were associated with the greatest odds of futility. Meanwhile, receipt of any systemic therapy (OR: 0.33; 95% CI: 0.31–0.34), receipt of any radiation (OR: 0.60; 95% CI: 0.57–0.63), and receipt of neoadjuvant systemic therapy (OR: 0.62; 95% CI: 0.57–0.66) were associated with the lowest odds of futility. In the neoadjuvant subgroup, a longer diagnosis‐to‐surgery interval was associated with lower odds of futility.
Conclusion
PD was futile in about one quarter of patients. Futility was associated with higher age and worse tumor biology. Receipt of neoadjuvant therapy resulted in fewer futile operations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Surgical Oncology, Department of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Division of Hematology, Oncology, and Palliative Care, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Förderung
- BLRD VA
- NCI NIH HHS
- NHGRI NIH HHS
- National Human Genome Research Institute
Zitieren
APA
Marcinak, C. T., Ahmed, K. S., LoConte, N. K., Praska, C. E., Varley, P. R., Weber, S. M., Abbott, D. E., Ronnekleiv-Kelly, S. M., Kratz, J. D., Lubner, S. J., Minter, R. M., & Zafar, S. N. (2024). Understanding futility in pancreaticoduodenectomy: Insights from a national cohort. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27773
Vancouver
Marcinak CT, Ahmed KS, LoConte NK, Praska CE, Varley PR, Weber SM, et al. Understanding futility in pancreaticoduodenectomy: Insights from a national cohort. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27773
BibTeX
@article{Marcinak2024,
author = {Marcinak, Clayton T and Ahmed, Kaleem S and LoConte, Noelle K and Praska, Corinne E and Varley, Patrick R and Weber, Sharon M and Abbott, Daniel E and Ronnekleiv-Kelly, Sean M and Kratz, Jeremy D and Lubner, Sam J and Minter, Rebecca M and Zafar, Syed Nabeel},
title = {Understanding futility in pancreaticoduodenectomy: Insights from a national cohort},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27773}
}
EUVIMED